Metraipolis › archive › dc_fba6cdaa042b
Sex representation in trials relative to indication-specific disease burden in FDA-approved drugs (2015-2023) — Europe PMC PMID:42336860
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42336860
- DOI
- 10.1038/s41467-[numero omesso]-z
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T05:43:24.144Z
- SHA-256 of the archived text
788ab6a1e4b4dbacb1ea2833459101481f97e3482dcbce94bba77b5337098d5b- Stable URL of this page
https://metraipolis.com/documento/dc_fba6cdaa042b
How to cite
Sex representation in trials relative to indication-specific disease burden in FDA-approved drugs (2015-2023) — Europe PMC PMID:42336860 — Europe PMC (en), https://europepmc.org/article/MED/42336860 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fba6cdaa042b (Metraipolis archive dc_fba6cdaa042b, sha256 788ab6a1e4b4dbacb1ea2833459101481f97e3482dcbce94bba77b5337098d5b)
BibTeX
@misc{dcfba6cdaa042b,
title = {Sex representation in trials relative to indication-specific disease burden in FDA-approved drugs (2015-2023) — Europe PMC PMID:42336860},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42336860},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fba6cdaa042b; sha256 788ab6a1e4b4dbacb1ea2833459101481f97e3482dcbce94bba77b5337098d5b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42336860. Agents can read the archived copy with the MCP tool read_document.